Document is current
Any future updates will be listed below
-
Authors
van Leeuwen, Jenna E. http://orcid.org/0000-0002-4744-2960
Ba-Alawi, Wail http://orcid.org/0000-0002-2747-4703
Branchard, Emily
Cruickshank, Jennifer
Schormann, Wiebke http://orcid.org/0000-0003-3055-2706
Longo, Joseph http://orcid.org/0000-0002-9580-5105
Silvester, Jennifer
Gross, Peter L. http://orcid.org/0000-0002-8698-7074
Andrews, David W. http://orcid.org/0000-0002-9266-7157
Cescon, David W. http://orcid.org/0000-0002-1080-0998
Haibe-Kains, Benjamin
Penn, Linda Z. http://orcid.org/0000-0001-8133-5459
Gendoo, Deena M. A. http://orcid.org/0000-0001-8891-4138
-
Funding
Funding for this research was provided by:
Terry Fox Research Institute (1064)
- License Information
-
More Information
Article History
Received: 2 February 2021
Accepted: 2 September 2022
First Online: 24 October 2022
Competing interests
: DWC serves as a consultant for AstraZeneca, Exact Sciences, Eisai, Gilead, GlaxoSmithKline, Inivata, Merck, Novartis, Pfizer, and Roche.; receives research support (to institution) from AstraZeneca, Gilead, GlaxoSmithKline, Inivata, Merck, Pfizer, and Roche, and holds intellectual property as co-inventor on a patent (US62/675,228) titled “Methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene”. DWA serves as a consultant for Roivent, Saguaro, and Precision Cancer Technologies; receives research support (to the institution) from Novartis and holds intellectual property as co-inventor on patents related to in vitro evolution and regulation of protein translation (WO9837186 titled “In vitro peptide or protein expression library” and US5/807,707/US5/824,497 titled “High-efficiency translation of mRNA molecules”). All other authors declare no competing interests.
